The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes (Nexium)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00699426|
Recruitment Status : Completed
First Posted : June 18, 2008
Last Update Posted : September 3, 2012
To test the effect of Nexium and probiotics on insulin secretion and cardiovascular risk factors on type 2 diabetic patients.
- Nexium causes an increased gastrin secretion that increases the insulin secretion and thereby a reduction of HbA1c
- Probiotics changes the gut flora and bloodpressure
- Probiotics causes a change in inflammation and thrombosis.
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes||Drug: nexium Dietary Supplement: Yoghurt Drug: placebo+placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||41 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||The Effect of Nexium and Cardi-04 Yoghurt on Insulin Secretion and Effect and Cardi Vascular Risk Factors Associated With the Insulin Syndrome in Patients With Type 2 Diabetes - a Randomized Double-blind, Prospective, Placebo Controlled 2 x 2 Factorial Design 3 Month's Study.|
|Study Start Date :||June 2008|
|Actual Primary Completion Date :||June 2009|
|Actual Study Completion Date :||June 2009|
|Active Comparator: Nexium + Yoghurt||
40 mg once daily is tested together with Yoghurt
|Placebo Comparator: Nexium + Placebo||
nexium and placebo are tested
|Placebo Comparator: Placebo+ Yoghurt||
Dietary Supplement: Yoghurt
|Placebo Comparator: placebo+placebo||
placebo and placebo are tested.
- insulin secretion [ Time Frame: 1 year ]
- blood pressure [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00699426
|Principal Investigator:||Allan A. Vaag, MD, DMSc||Steno Diabetes Center Copenhagen|